On December 1, 2021 C-BioMex, a company specializing in the development of new peptide drugs, and Triore, an innovative company in novel antibody-drug conjugates, reported that they have signed a joint development agreement for a next-generation PDC drug utilizing both companies’ proprietary platform technologies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under this agreement, we plan to discover PDC candidate substances for two anticancer targets by utilizing CUSTM, a chemical-based peptide discovery platform technology from C-BioMex, and SIGT, a linker-toxin platform technology developed in-house by Triore.
Now that initial verification of the platform technologies of both companies has been completed, we aim to proceed with research and development rapidly and finalize candidate substances within two years.
Triore linker-toxin technology is a technology that can enhance the efficacy and safety of various therapeutic agents through a safe structure that is very stable in the blood and releases drugs only in specific environments.
The two companies plan to develop a PDC with both global competitiveness and marketability by applying triore linker-toxin technology to two target peptides that were discovered through C-BioMex’s proprietary platform technology (CUSTM) and demonstrated high binding affinity and selectivity in in-vivo models.
"With this contract, we have expanded our company’s research scope from existing peptide-based radiotherapeutics to drug conjugates," said C-BioMex CEO Cha Jun-hoe. "We are very pleased to collaborate with Triore, which possesses expertise in the linker-toxin field, and we have high expectations that we can develop an excellent PDC based on the expertise and passion of both companies."
"Through this research agreement, we look forward to developing a safe and highly effective PDC by combining C-BioMex’s expertise in the peptide field with our technology," said Woo Seong-ho, CEO of Triore. "We will cooperate closely with both companies to ensure the rapid development of new therapeutic agents."
(Press release, TriOar Biotechnology, DEC 1, 2021, View Source;idx=1 [SID1234664782])